论文部分内容阅读
尽管放、化疗对霍奇金氏病(HD)的治愈率较高.但最终至少有1/3的进展期病人治疗失败。采用双特异性单克隆抗体进行的免疫治疗,可能对这类患者有效。HRS-3/Aq即抗CD16/CD30双克隆特异性抗体,它的一端连接于NK细胞及单核巨噬细胞所表达的Fcr-受体Ⅲ区(CD16抗原),另一端与HD及Reed-Srernberg细胞上的CD30抗原相联。体外实验及动物模型发现,HRS-3/Aq可特异性诱导CD30~+肿瘤细胞溶解,且可直接激活NK细胞,从而杀伤肿瘤细胞,单次剂量即可使完全缓解率达100％。本文报告HRS-3/Aq对15例难
Although radiotherapy and chemotherapy have a higher cure rate for Hodgkin’s disease (HD), at least one third of patients with advanced disease eventually fail treatment. Immunotherapy with bispecific monoclonal antibodies may be effective in these patients. HRS-3/Aq is an anti-CD16/CD30 double-clone specific antibody. One end thereof is linked to the Fcr-receptor III region (CD16 antigen) expressed by NK cells and monocyte macrophages, and the other end is associated with HD and Reed- The CD30 antigen on Srernberg cells is linked. In vitro experiments and animal models found that HRS-3/Aq can specifically induce CD30~+ tumor cell lysis, and can directly activate NK cells, thereby killing tumor cells, and the complete remission rate can reach 100% after a single dose. This article reports that HRS-3/Aq is difficult for 15 cases